Trial reportCancer research2018
IL1 Receptor Antagonist Controls Transcriptional Signature of Inflammation in Patients with Metastatic Breast Cancer.
Open access · bronzeAbstract readClinical Trial
In one paragraph
Trial report in Cancer research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 98 papers.
0numbers the graph read from it
0cells of the map it votes in
98citing papers in PubMed
7.3field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
98 citing papers in PubMed, 161 citations in OpenAlex.
- Blocking IL-1β reverses the immunosuppression in mouse breast cancer and synergizes with anti-PD-1 for tumor abrogation.Proceedings of the National Academy of Sciences of the United States of America · 2019Trial
- Chronic IL-1 Exposure Attenuates IL-1 Response and Alters Gene Expression Regulation While Maintaining Therapeutic Sensitivity in BCa Cell Lines.International journal of molecular sciences · 2026Article
- Review
- IL1R2 Deficiency Unleashes Neutrophil-Mediated Antitumor Potential in Sarcoma.Cancer immunology research · 2026Article
- A Literature Review of Interleukins in the Development and Treatment of Breast Cancer.International journal of molecular sciences · 2026Review
- AK4 promotes nasopharyngeal carcinoma metastasis and chemoresistance by activating NLRP3 inflammatory complex.Cell death & disease · 2025Article
- Interleukin-1β mediates a tumor-supporting environment prompted by IGF1 in triple-negative breast cancer (TNBC).Journal of translational medicine · 2025Article
- Targeting kinases that regulate programmed cell death: a new therapeutic strategy for breast cancer.Journal of translational medicine · 2025Review
- Exploring thymic stromal lymphopoietin in the breast cancer microenvironment: A preliminary study.Oncology letters · 2025Article
- Characterization of canine tumor-infiltrating leukocyte transcriptomic signatures reveals conserved expression patterns with human osteosarcoma.Cancer immunology, immunotherapy : CII · 2025Article
- Tumor microenvironment regulation by reactive oxygen species-mediated inflammasome activation.Archives of pharmacal research · 2025Review
- TSLP: contrasting roles in cancer.Frontiers in immunology · 2025Review
- Inhibition of Notch enhances efficacy of immune checkpoint blockade in triple-negative breast cancer.Science advances · 2024Article
- Computational immune synapse analysis reveals T-cell interactions in distinct tumor microenvironments.Communications biology · 2024Article
- Novel Treatments in Refractory Recurrent Pericarditis.Pharmaceuticals (Basel, Switzerland) · 2024Review
- The Roles of T cells in Immune Checkpoint Inhibitor-Induced Arthritis.Aging and disease · 2024Review
- Anakinra-Loaded Sphingomyelin Nanosystems Modulate In Vitro IL-1-Dependent Pro-Tumor Inflammation in Pancreatic Cancer.International journal of molecular sciences · 2024Article
- Targeting cytokine and chemokine signaling pathways for cancer therapy.Signal transduction and targeted therapy · 2024Review
- MMP1, IL-1β, sTNFR-1, and IL-6 are prognostic factors for patients with unresectable or metastatic renal cell carcinoma treated with immune checkpoint inhibitors.International journal of clinical oncology · 2024Article
- Tumor Cell-Associated IL-1α Affects Breast Cancer Progression and Metastasis in Mice through Manipulation of the Tumor Immune Microenvironment.International journal of molecular sciences · 2024Article
38 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
26 authors at 6 institutions in 1 country.
Te-Chia Wu *Baylor Institute for Immunology Research, Baylor Research Institute, Dallas, Texas.
Kangling Xu *Baylor Institute for Immunology Research, Baylor Research Institute, Dallas, Texas.
Jan Martinek *Baylor Institute for Immunology Research, Baylor Research Institute, Dallas, Texas.
Robyn R YoungThe Center for Cancer and Blood Disorders, Fort Worth, Texas.
Romain BanchereauBaylor Institute for Immunology Research, Baylor Research Institute, Dallas, Texas.
Joshy GeorgeThe Jackson Laboratory for Genomic Medicine, Farmington, Connecticut.
Jacob TurnerBaylor Institute for Immunology Research, Baylor Research Institute, Dallas, Texas.
Kyung In KimThe Jackson Laboratory for Genomic Medicine, Farmington, Connecticut.
Sandra ZurawskiBaylor Institute for Immunology Research, Baylor Research Institute, Dallas, Texas.
Xuan WangBaylor Institute for Immunology Research, Baylor Research Institute, Dallas, Texas.
Derek BlankenshipBaylor Institute for Immunology Research, Baylor Research Institute, Dallas, Texas.
Hannah M BrookesThe Jackson Laboratory for Genomic Medicine, Farmington, Connecticut.
Florentina MarchesBaylor Institute for Immunology Research, Baylor Research Institute, Dallas, Texas.
Gerlinde ObermoserBaylor Institute for Immunology Research, Baylor Research Institute, Dallas, Texas.
Elizabeth LavecchioBaylor Institute for Immunology Research, Baylor Research Institute, Dallas, Texas.
Maren K LevinBaylor Institute for Immunology Research, Baylor Research Institute, Dallas, Texas.
Sookyoung BaeThe Jackson Laboratory for Genomic Medicine, Farmington, Connecticut.
Cheng-Han ChungBaylor Institute for Immunology Research, Baylor Research Institute, Dallas, Texas.
Jennifer L SmithBaylor Institute for Immunology Research, Baylor Research Institute, Dallas, Texas.
Alma-Martina CepikaBaylor Institute for Immunology Research, Baylor Research Institute, Dallas, Texas.
Kyp L OxleyBaylor Institute for Immunology Research, Baylor Research Institute, Dallas, Texas.
George J SnipesBaylor University Medical Center, Sammons Cancer Center, Dallas, Texas.
Jacques BanchereauBaylor Institute for Immunology Research, Baylor Research Institute, Dallas, Texas.
Virginia PascualBaylor Institute for Immunology Research, Baylor Research Institute, Dallas, Texas.
Joyce O'ShaughnessyBaylor University Medical Center, Charles A. Sammons Cancer Center, Texas Oncology, Dallas, Texas.
A Karolina PaluckaBaylor Institute for Immunology Research, Baylor Research Institute, Dallas, Texas. karolina.palucka@jax.org.
Baylor Institute for Rehabilitation · USJackson Laboratory · USBaylor University · USBaylor University Medical Center · USCenter for Cancer and Blood Disorders · USTexas Oncology · US
Funding
Shared Resource ManagementP30CA034196 · NCI · JACKSON LABORATORY · PI William Carl Skarnes · 1985 to 2026
$61.9MNCI NIH HHS P30 CA034196
Abstract
Inflammation affects tumor immune surveillance and resistance to therapy. Here, we show that production of IL1β in primary breast cancer tumors is linked with advanced disease and originates from tumor-infiltrating CD11c
Indexed as
Gene Expression Regulation, NeoplasticTranscription, GeneticAnimalsBreast NeoplasmsCapecitabineCD11c AntigenCell Line, TumorCell MembraneFemaleFuransHumansInflammationInterleukin-1betaInterleukin 1 Receptor Antagonist ProteinKetonesLeukocytes, MononuclearCapecitabineCD11c AntigeneribulinFuransIL1RN protein, humanInterleukin-1betaInterleukin 1 Receptor Antagonist ProteinKetonesPaclitaxelPolyether PolyketidesTransforming Growth Factor beta
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.